🎙️ Sub11: Control Bionics — EMG, Impact & Innovation

In this episode of Sub11, Chris Titley sits down with Jeremy Steele, CEO of ASX-listed medtech company Control Bionics.

Jeremy unpacks how a pioneering Australian technology—originally used by Stephen Hawking—is now changing lives across assistive communication, rehabilitation, and sports performance. From enabling non-verbal individuals to communicate, to boosting vertical jump height in elite athletes, Control Bionics is using surface electromyography (EMG) to interpret human intent like never before.

We discuss:

• How the NeuroNode and NeuroStrip work
• Partnerships and global expansion
• Their recent investment in NeuroBounce
• AI’s role in personalised performance and injury prevention
• Commercial traction, regulatory wins, and blue-sky potential

Plus, Jeremy shares a moving story of a young man in Japan who used the technology to speak to his mother for the first time in 20 years.

This is a 101 on a company using Australian-born tech to create global impact.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Control Bionics and Sub11 are in a commercial relationship which includes the production of media assets for use on LinkedIn. All questioning is created by Sub11, not Control Bionics.

This interview mainly discussed the journey and evolution of Audeara, a hearing health technology company founded by James Fielding.

The conversation covered the company's inception in 2015, its transition from a B2C to a B2B model, and its current position as a global player in the hearing health industry.

James Fielding detailed the company's initial focus on creating headphones with built-in hearing tests, which evolved into personalized audio solutions.

He highlighted key milestones such as their successful Kickstarter campaign in 2017, the challenges of product development and delivery, and securing government contracts and partnerships with major audiology companies worldwide.

The interview also touched on Audeara's shift towards licensing their technology to other brands, their expansion into international markets, particularly Asia, and their recent financial successes. Fielding emphasised the company's commitment to improving hearing health awareness and accessibility, discussing partnerships with companies like Zildjian and their entry into the Chinese medical device market.

The conversation concluded with insights into Audeara's future growth strategies, the balance between growth and capital efficiency, and the company's progress towards profitability.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Audeara and Sub11 are in a commercial relationship which includes production of media mediums such as video, audio and social media. All questioning is created by Sub11, not Audeara.

The podcast is an interview with James Durrant, the Managing Director of RareX, an ASX-listed company focused on rare earth elements (REEs) and phosphate mining.

James discusses his background as a mining engineer and his experience working for companies like BHP Billiton before joining RareX.

He explains the importance of REEs in modern technology, particularly in electric vehicles, wind turbines, and defense systems.

RareX's main project is the Cummins Range project in Australia, which contains significant deposits of REEs and phosphate.

The company plans to develop the phosphate aspect first as a low-cost entry point before moving into REE production.

James also mentions RareX's recent acquisition of the Khaleesi project, which is prospective for REEs, niobium, base metals, and precious metals.

The company is exploring opportunities for expansion, particularly in Saudi Arabia and Eastern Africa, to leverage its expertise and become a near-term developer of REE projects.

Key catalysts for investors in the next 12 months include drilling at the Khaleesi project, progress on the Cummins Range project's engineering and approvals, and potential strategic deals for project expansion.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.